ClinicalTrials.gg
Active, not recruitingNCT06260709Updated Oct 9, 2026

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

A Phase 2 interventional study of NNC6019-0001 in Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S. Active, not recruiting at 38 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Updated Oct 9, 2026Enrollment updatedPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for approximately 6 years or until NNC6019-0001 is commercially or otherwise available to the participant, whichever comes first.

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy (ATTR CM)
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed study intervention in NN6019-4940 and attended the last study visit (week 64; visit 16), and no later than 12 weeks after visit 16.
  • Expected to be on stable doses of cardiovascular medical therapy 6 weeks prior to the enrolment visit.

Exclusion criteria

Exclusion Criteria:

  • A prior solid organ transplant.
  • Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in-situ carcinomas of the cervix, or in-situ/high grade prostatic intraepithelial neoplasia (PIN) or low-grade prostate cancer) within 5 years before screening.
  • Current treatment with calcium channel blockers with conduction system effects (e.g., verapamil, diltiazem). The use of dihydropyridine calcium channel blockers is allowed. The use of digoxin will only be allowed if required for management of atrial fibrillation with rapid ventricular response.
  • Body weight greater than (>) 120 kilograms (kg) (264.6 pounds [lb]) at screening.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    NNC6019-0001

    Participants will receive NNC6019-0001 intravenously every 4 weeks added to the standard of care up to 300 weeks.

    Drug: NNC6019-0001

Interventions

  • Intravenous NNC6019-0001 every 4 weeks added to the standard of care up to 300 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as events.

    Time frame: From baseline (week 0) to up to 6 years

Secondary outcomes

  1. Change in 6-Minute Walk Test (6MWT)

    Measured in meters.

    Time frame: From baseline (week 0) to visit 28 (week 104)

  2. Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)

    Measured in percentage.

    Time frame: From baseline (week 0) to visit 28 (week 104)

  3. Change in Myocardial Extracellular Volume (ECV)

    Measured in percentage-points.

    Time frame: From baseline (week 0) to visit 28 (week 104)

  4. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)

    The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Measured in score on a scale.

    Time frame: From baseline (week 0) to visit 28 (week 104)

  5. Change in Troponin I

    Measured in nanogram per milliliter (ng/mL).

    Time frame: From baseline (week 0) to visit 28 (week 104)

  6. Change in Global Longitudinal Strain (GLS) on Echocardiography

    Measured in percentage-points.

    Time frame: From baseline (week 0) to visit 28 (week 104)

07

Study locations

38 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 48 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2028 → Feb 2030, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 15, 2024
StartActual
Feb 20, 2024
Primary completionEst.
Feb 29, 2028
CompletionEst.
Feb 9, 2030was Aug 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 3 sites removed
Show 6 added (2 Japan, 2 Portugal, 1 France, 1 Netherlands)
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil · Toulouse, France
  • Hiroshima University hospital_Cardiovascular Medicine · Hiroshima, Japan
  • UMC Utrecht · Utrecht, Netherlands
  • ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães · Guimarães, Portugal
  • ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real · Vila Real, Portugal
  • Okayama University Hospital_Cardiovascular Medicine · Okayama, Japan
Show 3 removed
  • Unidade Local de Saude do Alto Ave, E.P.E. · Guimarães, Portugal
  • Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E. · Vila Real, Portugal
  • Okayama University Hospital_Cardiovascular Medicine · Okayama-shi, Okayama, Japan
across 2 updates, Sep 30, 2026 – Oct 9, 2026
Study completion
Aug 15, 2028→Feb 9, 2030
Sep 30, 2026
Enrollment
80→88
Oct 9, 2026
Primary outcomes
Revised in 2 updates
What changed on Sep 30, 2026
  • EditedNumber of Treatment Emergent Adverse Events (TEAEs)Time frame: From baseline (week 0) up to visit 39 (week 156)
What changed on Oct 9, 2026
  • Time frameNumber of Treatment Emergent Adverse Events (TEAEs)From baseline (week 0) up to visit 39 (week 156) → From baseline (week 0) to up to 6 years
across 2 updates, Sep 30, 2026 – Oct 9, 2026
Show all 2 updates
  1. Oct 9, 2026
    1 site added, 1 site removed
    Show site
    • Okayama University Hospital_Cardiovascular Medicine · Okayama, Japan
    Show 1 removed
    • Okayama University Hospital_Cardiovascular Medicine · Okayama-shi, Okayama, Japan
    Enrollment 80→88
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Treatment Emergent Adverse Events (TEAEs)From baseline (week 0) up to visit 39 (week 156) → From baseline (week 0) to up to 6 years
    + 3 other changes: verification date, description and arm descriptions
  2. Sep 30, 2026
    5 sites added, 2 sites removed
    Show 5 added (2 Portugal, 1 France, 1 Japan, 1 Netherlands)
    • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil · Toulouse, France
    • Hiroshima University hospital_Cardiovascular Medicine · Hiroshima, Japan
    • UMC Utrecht · Utrecht, Netherlands
    • ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães · Guimarães, Portugal
    • ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real · Vila Real, Portugal
    Show 2 removed
    • Unidade Local de Saude do Alto Ave, E.P.E. · Guimarães, Portugal
    • Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E. · Vila Real, Portugal
    Study completion Aug 15, 2028→Feb 9, 2030
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Treatment Emergent Adverse Events (TEAEs)Time frame: From baseline (week 0) up to visit 39 (week 156)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06260709
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 15, 2024
Start date
Feb 20, 2024
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 9, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC6019-0001

Start the discussion